Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 30, 2026

Oct 30, 2026

•

3 min read

Biotech & Pharma Updates | October 30, 2026

🧬 Regeneron reports "clean sweep" Q3 with $5.1B revenue, 36% growth; key pipeline catalysts ahead, Bambusa Therapeutics prices upsized $168.9M IPO, developing bispecific antibodies for immunology, Gilead Sciences' Q3 HIV sales surge 18% to $6.2B, driving highest annual growth since 2015

Christian Cuchapin, +1

Biotech & Pharma Updates | October 29, 2026

Oct 29, 2026

•

3 min read

Biotech & Pharma Updates | October 29, 2026

🧬 Eli Lilly's 2026 guidance jumps $10B as GLP-1 sales, Medicare Bridge program exceed expectations, Lonza expands Swiss ADC manufacturing hub in Visp, adding mid-scale bioconjugation suites for 2028 launch, Flagship Pioneering merges Etiome, Cellarity, and Empress Therapeutics into new AI drug discovery venture Etcelera

Christian Cuchapin, +1

Biotech & Pharma Updates | October 28, 2026

Oct 28, 2026

•

3 min read

Biotech & Pharma Updates | October 28, 2026

🧬 Eli Lilly's (retatrutide) beats Novo's Ozempic in Ph3 trial for type 2 diabetes on blood sugar and weight loss, Biogen posts third consecutive quarter of revenue growth, reaching $2.8B with Apellis integration boost, Ferring Pharmaceuticals to acquire Gameto for up to $1.4B, adding next-gen IVF technology Fertilo

Christian Cuchapin, +1

Biotech & Pharma Updates | October 27, 2026

Oct 27, 2026

•

3 min read

Biotech & Pharma Updates | October 27, 2026

🧬 GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) nearly quadruples progression-free survival in Ph3 B7-H3-targeted osteosarcoma trial, Anthropic files IPO, revealing drug R&D ambitions including molecular biology lab and pharma partnerships, FDA approves Pfizer's Talzenna (talazoparib)-Xtandi (enzalutamide) combo for HRR-mutated metastatic hormone-sensitive prostate cancer based on Ph3 data

Christian Cuchapin, +1

Biotech & Pharma Updates | October 26, 2026

Oct 26, 2026

•

4 min read

Biotech & Pharma Updates | October 26, 2026

🧬 Akeso, Summit Therapeutics' (ivonescimab) beats AstraZeneca's Imfinzi in Ph3 biliary tract cancer trial with 25% lower death risk, Pathos AI raises $237M Series E, led by Bristol Myers Squibb, scaling AI-driven drug development platform, Johnson & Johnson's JNJ-6143 (JNJ-6143) shows 75% overall response rate in Ph1 metastatic castration-resistant prostate cancer trial

Christian Cuchapin, +1

Biotech & Pharma Updates | October 23, 2026

Oct 23, 2026

•

3 min read

Biotech & Pharma Updates | October 23, 2026

🧬 Gilead Sciences acquires PepStar Therapeutics' IL-23R inhibitor program for $1.3B upfront, Alnylam plans pivotal trial for brezosiran (ALN-HTT02) targeting huntingtin protein in Huntington's disease after Ph1b success, FDA lifts clinical hold on Aardvark Therapeutics' ARD-101 after new cardiac safety data clears concerns

Christian Cuchapin, +1

Biotech & Pharma Updates | October 22, 2026

Oct 22, 2026

•

3 min read

Biotech & Pharma Updates | October 22, 2026

🧬 Roche's Vabysmo hits $1.38B quarterly sales, meets analyst expectations after prolonged growth slowdown, AstraZeneca's Ultomiris (ravulizumab) wins FDA accelerated approval for immunoglobulin A nephropathy, its fifth indication, FDA accepts Biohaven's Vyglxia (troriluzole) resubmission for spinocerebellar ataxia with advisory committee meeting planned

Christian Cuchapin, +1

Biotech & Pharma Updates | October 21, 2026

Oct 21, 2026

•

3 min read

Biotech & Pharma Updates | October 21, 2026

🧬 GSK, Ionis Pharmaceuticals win FDA approval for Hibsago (bepirovirsen) targeting hepatitis B virus in chronic hepatitis B infection following Ph3 success, Priovant Therapeutics seeks label expansion for Lisraya (brepocitinib) after Ph3 success in non-infectious uveitis, OpenAI acquires Orchestra Bio, combining AI platforms to accelerate drug development workflows

Christian Cuchapin, +1

Biotech & Pharma Updates | October 20, 2026

Oct 20, 2026

•

3 min read

Biotech & Pharma Updates | October 20, 2026

🧬 GSK's Jemperli (dostarlimab) receives FDA accelerated approval for MSI-H/dMMR locally advanced rectal cancer based on Ph2 data, Eli Lilly, METiS TechBio partner on AI-driven LNP drug delivery platform, up to $1.1B milestones, Gilead Sciences' (emvistegrast) meets Ph2 primary endpoint in moderately to severely active ulcerative colitis, Ph3 planned

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | October 30, 2026

Biotech & Pharma Updates | October 29, 2026

Biotech & Pharma Updates | October 28, 2026

Biotech & Pharma Updates | October 27, 2026

Biotech & Pharma Updates | October 26, 2026

Biotech & Pharma Updates | October 23, 2026

Biotech & Pharma Updates | October 22, 2026

Biotech & Pharma Updates | October 21, 2026

Biotech & Pharma Updates | October 20, 2026

TLDR Biotech

FAQ

Media Partners